Details of the Drug Combination

General Information of Drug Combination (ID: DCGZRKA)

Drug Combination Name
Febuxostat M102
Indication
Disease Entry Status REF
Hyperuricemia Phase 2 [1]
Component Drugs Febuxostat   DMDEXQ0 M102   DMUFIO9
Small molecular drug N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Febuxostat
Disease Entry ICD 11 Status REF
Hyperuricaemia 5C55.Y Approved [2]
Febuxostat Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Xanthine dehydrogenase/oxidase (XDH) TT7RJY8 XDH_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Febuxostat Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Febuxostat Interacts with 11 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Ras-related protein M-Ras (MRAS) OTNCVCQW RASM_HUMAN Increases Expression [4]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Increases Expression [4]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [7]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Expression [7]
Nuclear receptor subfamily 4immunitygroup A member 1 (NR4A1) OTGP6GA4 NR4A1_HUMAN Increases Expression [4]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Phosphorylation [4]
Dual specificity protein phosphatase 4 (DUSP4) OT6WAO12 DUS4_HUMAN Increases Expression [4]
Dual specificity protein phosphatase 8 (DUSP8) OTPLMPG9 DUS8_HUMAN Increases Expression [4]
Dual specificity protein phosphatase 5 (DUSP5) OTH96RA7 DUS5_HUMAN Increases Expression [4]
Interleukin-1 receptor accessory protein (IL1RAP) OTEU321R IL1AP_HUMAN Increases Expression [4]
Dual specificity protein phosphatase 10 (DUSP10) OTNG467B DUS10_HUMAN Increases Expression [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DOT(s)
Indication(s) of M102
Disease Entry ICD 11 Status REF
Amyotrophic lateral sclerosis 8B60.0 Preclinical [3]
M102 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Nuclear factor erythroid 2-related factor 2 (Nrf2) TTA6ZN2 NF2L2_HUMAN Activator [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Gout DC0WGVW N. A. Phase 2 [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01416402) Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6817).
3 Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
4 Febuxostat Increases Ventricular Arrhythmogenesis Through Calcium Handling Dysregulation in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol Sci. 2022 Sep 24;189(2):216-224. doi: 10.1093/toxsci/kfac073.
5 Clinical pipeline report, company report or official report of Takeda (2009).
6 In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008 May;38(5):496-510.
7 Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells. J Appl Toxicol. 2016 Sep;36(9):1120-8. doi: 10.1002/jat.3272. Epub 2015 Dec 7.
8 Clinical pipeline report, company report or official report of Aclipse Therapeutics.
9 ClinicalTrials.gov (NCT02252835) Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout